TESARO (NASDAQ:TSRO) had its price target decreased by analysts at Morgan Stanley from $156.00 to $146.00 in a research report issued on Thursday. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target would suggest a potential upside of 164.35% from the stock’s previous close.
TSRO has been the topic of a number of other reports. Jefferies Group restated a “hold” rating and set a $124.00 price objective on shares of TESARO in a research note on Friday, November 3rd. Credit Suisse Group restated an “outperform” rating and set a $150.00 price objective (down from $190.00) on shares of TESARO in a research note on Thursday, January 18th. Leerink Swann upgraded shares of TESARO from a “market perform” rating to an “outperform” rating in a research note on Wednesday, November 15th. BidaskClub upgraded shares of TESARO from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 23rd. Finally, Citigroup restated a “buy” rating and set a $135.00 price objective (down from $216.00) on shares of TESARO in a research note on Wednesday, December 20th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $133.39.
Shares of TESARO (TSRO) traded down $6.32 during midday trading on Thursday, hitting $55.23. 4,730,600 shares of the company were exchanged, compared to its average volume of 1,219,060. TESARO has a fifty-two week low of $52.20 and a fifty-two week high of $184.00. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $3,000.00, a PE ratio of -6.02 and a beta of 1.25.
In related news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 40.50% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of TSRO. Nationwide Fund Advisors increased its stake in TESARO by 63.1% in the 3rd quarter. Nationwide Fund Advisors now owns 61,500 shares of the biopharmaceutical company’s stock worth $7,940,000 after purchasing an additional 23,800 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in TESARO in the 3rd quarter worth about $230,000. NJ State Employees Deferred Compensation Plan purchased a new position in TESARO in the 3rd quarter worth about $775,000. Tocqueville Asset Management L.P. increased its stake in TESARO by 26.4% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 99,330 shares of the biopharmaceutical company’s stock worth $12,824,000 after purchasing an additional 20,750 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in TESARO by 1.2% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 49,054 shares of the biopharmaceutical company’s stock worth $6,333,000 after purchasing an additional 570 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3230425/tesaro-tsro-price-target-cut-to-146-00-by-analysts-at-morgan-stanley.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.